Engflag

Cyclomine

Quick links to important sections

Cyclomine

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyclomine

Property Description
Active Ingredients Dicyclomine Hydrochloride, Paracetamol (Acetaminophen)
Form Tablet, Capsule, Oral Suspension
Pharmacological Class Antispasmodic, Non-opioid Analgesic
Common Use Symptomatic relief of pain and spasms
Origin Synthetic substance

What Type of Medicine is Cyclomine and What Does it Contain?

Cyclomine is defined as a fixed-dose combination (FDC) drug, a single preparation containing two distinct, chemically synthesized active ingredients: Dicyclomine Hydrochloride and Paracetamol. Both substances are of synthetic substance origin and are typically administered via the oral route, supplied as a tablet or capsule. As an FDC, its formulation strategy—uniting two agents in one unit—is widely accepted for addressing multi-symptom discomfort. This design positions Cyclomine distinctly from single-ingredient prescription options. Dicyclomine is used for its effects on intestinal motility. The Dicyclomine component works specifically to ease the physical discomfort caused by cramping muscles.

Cyclomine's Pharmacological Class and Dual Action

Cyclomine belongs to the therapeutic classes of Antispasmodic agents and Non-opioid Analgesic Compounds, reflecting the primary actions of its constituents. The Dicyclomine Hydrochloride component functions as an antispasmodic, primarily acting to induce smooth muscle relaxation. Concurrently, the Paracetamol (Acetaminophen) component serves as the analgesic (pain-relieving) and antipyretic (fever-reducing) agent, primarily affecting processes within the central nervous system. This dual classification signifies that the medicine is designed to simultaneously address the physical tension of muscle spasm and the resulting sensation of pain. The Paracetamol component is recognized for its role in reducing pain centrally.

What is the General Purpose of Cyclomine?

The general purpose of Cyclomine is to provide comprehensive symptomatic relief by combining intervention on both muscle tension and general discomfort. The drug is specifically formulated for situations characterized by both involuntary smooth muscle spasm and associated mild to moderate pain. This unique combination approach targets the physical cramp and the overall pain perception simultaneously, offering a functional benefit beyond what single-agent drugs provide for such scenarios. Its objective is the efficient, simultaneous symptomatic resolution of both the source of tension and the overall pain experience.

Regulatory References

  1. referenced in the NIH Drug Information Portal

What side effects are possible with Cyclomine?

Possible Side Effects and Safety Information

The official safety profile for Cyclomine, a combination of Dicyclomine (antispasmodic) and Paracetamol (analgesic), is characterized by two distinct safety patterns documented in regulatory labeling. The common adverse reactions are largely linked to the anticholinergic activity of Dicyclomine, while serious adverse reactions involve systemic risks associated with Paracetamol.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency according to regulatory standards:

  • Very Common: Dizziness, Dry Mouth, Blurred Vision.
  • Common: Nausea, Somnolence (Drowsiness), Constipation, Nervousness.
  • Rare: Urinary Retention, Psychosis, Blood Dyscrasias, Hepatic Dysfunction.

These effects are grouped across System-Organ Classes including Nervous System Disorders, Gastrointestinal Disorders, Eye Disorders, and Renal and Urinary Disorders.

Serious Adverse Reactions and Safety Constraints

The label notes a risk of Hepatic Failure and Hepatotoxicity, primarily associated with the Paracetamol component, particularly with excessive or long-term chronic use. Severe Hypersensitivity events, including anaphylaxis, and rare Serious Skin Reactions (e.g., Stevens-Johnson Syndrome) are also officially documented.

Safety constraints and population-specific considerations are mandatory. The medicine is contraindicated for infants less than six months of age and for patients with conditions exacerbated by anticholinergics, such as narrow-angle glaucoma or obstructive diseases of the gastrointestinal or urinary tracts. Older adults may have increased susceptibility to central nervous system effects, and use is constrained in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose profile for this fixed-dose combination involves two distinct toxicological risks and mandates immediate emergency action.

Overdose Presentation Key Manifestations (Regulatory-Documented)
Dicyclomine Component Acute Anticholinergic Effects, including confusion, hallucinations, agitation, slurred speech, tachycardia (rapid heart rate), dilated pupils (mydriasis), and dry mouth. Severe overdosage may lead to muscular paralysis [FDA].
Paracetamol Component Initial symptoms may be non-specific (pallor, nausea, vomiting) but can progress to life-threatening hepatic failure and acute renal failure up to 48 hours later. Laboratory findings may include metabolic acidosis [SmPC].

Immediate Action and Monitoring Mandates

Urgent medical advice/treatment must be sought immediately, even if the individual feels well, due to the documented risk of severe, delayed liver damage [SmPC]. Patients should be referred to the hospital urgently for monitoring and management.

Specific treatment protocols are documented:

  • Antidote: N-acetylcysteine (NAC) is the designated antidote for the Paracetamol component and should be administered without delay to prevent or lessen hepatic injury [FDA Antidote Label].
  • Supportive Measures: Management may include gastric lavage, administration of activated charcoal, and use of a cholinergic agent (if indicated) to counter severe anticholinergic effects [FDA].
  • Risk Factors: Individuals with conditions such as chronic alcohol dependency or those taking certain enzyme-inducing drugs are at increased risk for Paracetamol-induced liver damage [SmPC].

Therapeutic Uses of Cyclomine

Main Uses of Cyclomine

Cyclomine is primarily utilized for the management of functional bowel disorders and gastrointestinal motility issues. It is most commonly associated with the treatment of irritable bowel syndrome (IBS). The medication acts as an antispasmodic, targeting the smooth muscles of the gastrointestinal tract to alleviate symptoms associated with abnormal gut movement.

Relieving Gastrointestinal Spasms

The principal function of Cyclomine is to reduce the intensity and frequency of muscle spasms in the digestive system. By relaxing the smooth muscle walls of the stomach and intestines, the medication helps to stabilize the digestive process when it has become overactive or irregular.

Management of Irritable Bowel Syndrome (IBS)

In patients diagnosed with IBS, the digestive tract often reacts excessively to stimuli, leading to discomfort and irregular bowel patterns. Cyclomine is used to address the cramping and abdominal pain that characterize this condition. It helps to normalize the transit time of material through the gut, providing relief from the physical distress caused by hypermotility.

Benefits and Clinical Goals

The primary benefit of Cyclomine therapy is the improvement of daily comfort for individuals experiencing chronic digestive spasms.

  • Reduction of Abdominal Pain: By preventing the sudden, involuntary contractions of the intestinal muscles, the medication helps decrease the sharp pain often associated with bowel disorders.
  • Improvement of Gut Function: Regularizing the contractions of the gastrointestinal tract can lead to a more predictable digestive rhythm.
  • Symptomatic Relief: While it does not cure the underlying cause of bowel dysfunction, it provides a means of managing the physical manifestations of the condition, allowing for better management of symptoms during flare-ups.

Regulatory References

  1. NIH DailyMed official labeling

Eligibility and Restrictions for Use

Eligibility for Using Cyclomine (Dicyclomine/Paracetamol)

Official regulatory documentation defines eligibility for Cyclomine through strict population exclusions and restrictions based on age, physiological status, and underlying medical conditions. Use of this medication is primarily established for the adult population (age 18 and older).

Populations Who Must Not Use Cyclomine (Contraindications)

The medicine is formally contraindicated and must not be used in the following populations and conditions, according to official labeling:

  • Age: Infants less than 6 months of age.
  • Physiological Status: Nursing (breastfeeding) mothers.
  • Pre-existing Conditions: Patients diagnosed with closed-angle glaucoma, myasthenia gravis, or acute liver failure (due to the Paracetamol component).
  • Gastrointestinal Issues: Patients with obstructive disease of the GI tract, severe ulcerative colitis, or reflux esophagitis.

Restricted and Conditional Use

Regulatory labels specify that use requires caution in several other groups. Safety and effectiveness in children older than 6 months is generally not established in the U.S. label. Additionally, caution is mandated for older adults and individuals with pre-existing hepatic (liver) or renal (kidney) impairment, or unstable cardiovascular conditions, due to potential increased susceptibility to effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Cyclomine based on the distinct actions of its two components: Dicyclomine and Paracetamol.

Documented Pharmacodynamic and Exposure Interactions

Co-administration with other anticholinergic agents (such as certain antidepressants or antihistamines) or CNS depressants may reinforce the respective pharmacological effects of dicyclomine, potentially increasing drowsiness. Dicyclomine may also cause pharmacodynamic antagonism by counteracting the effects of prokinetic agents, like metoclopramide, which speed up gastrointestinal motility.

Exposure-modifying interactions include the effect of dicyclomine on slowly dissolving digoxin dosage forms, which may result in increased serum digoxin concentrations. Additionally, co-administration with warfarin or other oral anticoagulants may augment the anticoagulant effect (elevated INR) due to the paracetamol component.

Official Restrictions and Timing Rules

  • Other Acetaminophen Products: Co-administration with other acetaminophen-containing products is formally restricted to prevent exceeding the maximum total daily dose, which carries a risk of severe hepatotoxicity.
  • Alcohol: Consumption of three or more alcoholic drinks per day while using this medicine is associated with an officially documented risk of severe liver damage.
  • Antacids: Simultaneous oral administration should be avoided, and a dose separation of at least 2 hours is advised to mitigate interference with the absorption of the dicyclomine component.
  • Hepatic Status: The medicine is formally contraindicated in patients with severe hepatic impairment, as this condition heightens the risk of toxicity from the paracetamol component.

Mechanism of Action

Cyclomine (dicyclomine) functions via a dual-mechanism of action, modulating specific pathways to influence gastrointestinal smooth muscle activity. The primary mechanism involves cholinergic receptor antagonism. Cyclomine acts as an anticholinergic agent, competitively inhibiting the binding of the neurotransmitter acetylcholine to muscarinic receptors on smooth muscle cells. This interaction diminishes the cholinergic drive, resulting in a system-level consequence of reduced smooth muscle tone and inhibited peristaltic activity within the gastrointestinal tract. Additionally, Cyclomine exerts a direct musculotropic effect independent of the cholinergic system. This action involves interference with the intracellular processes that govern smooth muscle contractility, specifically modulating excitation-contraction coupling. By directly influencing these cellular mechanisms, the drug contributes to a reduction in baseline myocyte contractility, thereby regulating overactive cellular processes within the targeted muscle tissue.

Dosage and Administration Information

How Cyclomine is Used

The usage of Cyclomine, a fixed-dose combination (FDC) of Dicyclomine Hydrochloride and Paracetamol, follows a structured oral protocol to ensure consistent administration within a short-term treatment window.

Official Administration Guidelines

Usage Parameter Instruction
Route of Administration Primarily Oral (tablet, capsule, or solution). The single-agent Dicyclomine component is also available as an Intramuscular (IM) injection, restricted to short-term use (1–2 days) when oral intake is not possible.
Standard Dosing Schedule The standard adult oral dose for the Dicyclomine component begins at 20 mg four times a day (QID). This may be titrated up to a maximum of 40 mg QID (total daily dose 160 mg) based on tolerance.
Timing and Frequency The medication is typically taken four times a day (QID) and can be administered with or without food.
Treatment Duration Use is considered short-term. If adequate efficacy is not observed within two weeks, or if side effects prohibit a minimum daily dose of 80 mg, treatment should be discontinued.

Administration Requirements and Restrictions

Age-Specific Rules: The Dicyclomine component is contraindicated in infants under 6 months of age. Dosing for older adults should be initiated with caution at the low end of the adult range. Missed Dose Management requires skipping the missed dose and returning to the normal schedule; patients are instructed not to take extra doses to compensate.

Procedural Restrictions: Solid oral forms must be swallowed whole and not crushed. The IM form is strictly for the intramuscular route and must not be administered intravenously (IV).

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary for Combination Therapy (X and Y)

Research has evaluated whether the combination of X and Y affects the severity of chronic inflammatory back pain (CIBP). The reviewed studies focused on adults who met specific health criteria. Individuals with severe kidney disease were generally excluded from participation in the trials. In the reviewed studies, participant-reported outcomes were measured over several weeks.

Key Findings from Clinical Trials

Phase 3 clinical trials examined whether the X and Y combination was associated with changes in physical function and disease activity measures in participants with axial spondyloarthritis (AxSpA).

  • Physical Function: Researchers explored the effect of the combination on participant scores from standardized instruments designed to assess physical function over the study period.
  • Disease Activity: Measures of disease activity, such as C-reactive protein (CRP) levels and participant-reported disease scores, were monitored to see if they changed following the administration of the combination.
  • Pain Outcomes: Participant outcomes in the study included measurements of pain over time. Findings from a recent meta-analysis further analyzed the reported outcomes for pain in studies using this combination.

Markers and Study Protocols

Studies measured changes in inflammatory markers. Researchers explored the potential effects of the combination on markers of inflammation and disease activity, but the study design was not intended to assess long-term joint damage progression.

  • Pharmacology: Study protocols detailed the half-life and absorption rates of both X and Y when administered together.
  • Adherence: Adherence to the study's dosage protocol was recorded.

The primary studies focused on CIBP and AxSpA populations and did not evaluate outcomes for psoriatic arthritis.

Frequently Asked Questions (FAQ)

Common questions about Cyclomine (FAQ)

Q: What happens if I accidentally miss a dose of Cyclomine?

If a dose is missed, official prescribing information indicates continuing with the normal dosing schedule. The label specifically states not to take an extra dose to compensate for a missed one.

Q: How long can I safely take Cyclomine before my doctor should review treatment?

Official prescribing information indicates that treatment is typically discontinued if adequate efficacy is not observed within two weeks. The label also notes discontinuation criteria related to side effects prohibiting the maintenance of a minimum effective dose for the dicyclomine component.

Q: Can I drink alcohol while taking Cyclomine?

Official drug documentation includes specific warnings regarding alcohol consumption with this medication. The combination may increase central nervous system side effects, such as drowsiness, and also heightens the documented risk of liver damage associated with the paracetamol component.

Q: What is the expected onset of action after taking an oral dose of Cyclomine?

Based on the clinical pharmacology data, the dicyclomine component in Cyclomine is rapidly absorbed following oral administration. Peak concentrations of this component in the bloodstream are typically reached within approximately one to one and a half hours.

Q: Are there any known foods or drinks I should avoid while on this medication?

Official documentation specifically restricts alcohol consumption and advises that oral antacid products should be separated from Cyclomine administration. Outside of these specific interactions, official labeling generally indicates that patients can maintain a normal diet.

Q: Does Cyclomine contain any gluten, lactose, or other common allergens?

The official product label lists inactive ingredients, and some forms of the dicyclomine component may contain substances like anhydrous lactose. Reviewing the full list of inactive ingredients for the specific prescribed form is recommended if you have known allergies or sensitivities.

Q: If I have chronic constipation, will taking Cyclomine make it worse?

Regulatory warnings indicate that dicyclomine, as an anticholinergic medicine, works by reducing muscle movement in the gut and is listed as a cause of constipation. For individuals with pre-existing gastrointestinal conditions that involve reduced motility or obstruction, the medication is noted in the label for use with caution.

How should Cyclomine be stored and disposed of?

How to Store and Dispose of Cyclomine

The storage and disposal of Cyclomine (Dicyclomine Hydrochloride and Paracetamol/Acetaminophen) must adhere strictly to the conditions specified in the official regulatory labeling.

Official Storage Requirements

Cyclomine must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, which should be tightly closed to maintain product stability. Additionally, the product is required to be protected from light and must be kept out of the reach of children.

Disposal Instructions

Unused or expired Cyclomine must be disposed of according to local regulations. Official guidelines recommend utilizing authorized drug take-back programs and advise against discarding the medicine in household trash or pouring it into a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cyclomine found in:

A-Z Index: